Published in:
01-12-2015 | Original Paper
Pediatric gliosarcoma treated with adjuvant radiotherapy and temozolomide
Published in: Child's Nervous System | Issue 12/2015
Login to get accessAbstract
Purpose
Primary pediatric gliosarcoma (pPGS) is an extremely rare entity with only 25 cases reported in the English literature. The value of concurrent and adjuvant temozolomide is not known in this group of patient.
Methods
Five patients of pPGS treated from 2006 to 2011 were included in this retrospective analysis. All patients underwent maximal safe surgical resection. Adjuvant therapy included conformal radiation 60 Gy in 30 fractions (2 Gy daily for 5 days in a week) with concurrent temozolomide 75 mg/m2 daily followed by six cycles of maintenance temozolomide 150–200 mg/m2 (day 1 to day 5) every 4 weeks. We combined the survival data of 25 patients (already published) and five of our patients and analyzed them in terms of progression free survival (PFS) and overall survival (OS) using Kaplan–Meier method.
Results
Male to female ratio was 1:4 and median age was 12 years (range, 7–19 years). All but one patient underwent gross total resection and four patients completed adjuvant radiotherapy as well as concurrent and adjuvant temozolomide. At a median follow up of 22.6 months (range, 0 to 45.3 months), two patients were dead and two were alive without disease while one was lost to follow up. For the pooled data, estimated median PFS and OS of all 30 patients reported in literature were 12 and 43 months, respectively. Two years PFS and OS rate for all patients was 44.2 and 62.9 %, respectively.
Conclusion
Adjuvant radiotherapy and temozolomide is well tolerated and show an encouraging survival in pPGS.